Related Experiment Video
Updated: Aug 11, 2026
An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment
Published on: July 28, 2012
Chemosensitization of bladder cancer cells by survivin-directed antisense oligodeoxynucleotides and siRNA
Susanne Fuessel1, Jana Herrmann, Shuangli Ning
1Department of Urology, Technical University Dresden, Fetscherstr. 74, D-01307 Dresden, Germany. susanne.fuessel@uniklinikum-dresden.de
Abstract:
Survivin is known to be overexpressed in numerous tumor types including human bladder cancer and to cause resistance to radiation and chemotherapy. Therefore, we tested the antisense oligodeoxynucleotide AS-SVV286 and the small interfering RNA si-SVV284 to down-regulate survivin in the BCa cell lines EJ28 and 5637 thereby acting as sensitizers for chemotherapy. Pretreatment with these inhibitors followed by chemotherapy caused an enhanced decrease in cell viability. The observed reduction in cell counts associated with increased rates of apoptosis paralleled the degree of reduction of survivin expression that was achieved more efficiently by the siRNA than by the AS-ODN. Nevertheless, both therapy approaches in combination with all tested chemotherapeutics provoked a remarkable inhibition of viability and may serve as suitable additive tools for chemosensitization of bladder cancer cells.
Insights
Researchers investigated survivin inhibitors, AS-SVV286 and si-SVV284, to sensitize bladder cancer (BCa) cells to chemotherapy. Both inhibitors enhanced chemotherapy
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Survivin is overexpressed in many cancers, including bladder cancer.
- Survivin overexpression contributes to resistance against chemotherapy and radiation.
- Targeting survivin offers a potential strategy for enhancing cancer treatment efficacy.
Purpose of the Study:
- To evaluate the efficacy of survivin downregulation using AS-SVV286 and si-SVV284 in bladder cancer cells.
- To determine if survivin inhibition sensitizes bladder cancer cells to chemotherapy.
- To compare the effectiveness of antisense oligodeoxynucleotide (AS-ODN) and small interfering RNA (siRNA) in reducing survivin expression.
Main Methods:
- Utilized bladder cancer cell lines (EJ28 and 5637).
- Administered antisense oligodeoxynucleotide (AS-SVV286) and small interfering RNA (si-SVV284) to downregulate survivin.
- Applied chemotherapy in combination with survivin inhibitors.
- Assessed cell viability and apoptosis rates.
- Quantified survivin expression levels.
Main Results:
- Both AS-SVV286 and si-SVV284, when combined with chemotherapy, significantly reduced bladder cancer cell viability.
- si-SVV284 demonstrated higher efficiency in downregulating survivin expression compared to AS-SVV286.
- The reduction in cell counts and increase in apoptosis correlated with the degree of survivin expression reduction.
- Combined treatment strategies showed a remarkable inhibition of cell viability.
Conclusions:
- Survivin downregulation using AS-SVV286 and si-SVV284 effectively sensitizes bladder cancer cells to chemotherapy.
- siRNA (si-SVV284) is a more efficient tool for survivin inhibition than AS-ODN (AS-SVV286).
- These combined therapeutic approaches hold promise as additive tools for enhancing bladder cancer chemosensitization.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...